NCT07534371 2026-04-16
Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study
West China Hospital
Active not recruiting
Clinical Trials
10 trialsNCT07272512 2025-12-19
ZSPAC-17
Shanghai Zhongshan Hospital
Phase 4 Recruiting
NCT05077384 2025-09-16
Open-label Study of Surufatinib in Japanese Patients
Hutchmed
Phase 1/2 Completed
NCT04579679 2025-07-25
Open-Label Surufatinib in European Patients With NET
Hutchmed
Phase 2 Terminated
NCT04579757 2025-05-08
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
NCT05165407 2025-03-14
NESSIE
Peking University
Phase 2 Recruiting
NCT04814732 2024-04-12
Expanded Access Program of Surufatinib
Hutchmed
No longer available
NCT02588170 2023-03-30
Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
Hutchmed
Phase 3 Completed
NCT02589821 2023-03-30
Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
Hutchmed
Phase 3 Completed
NCT02267967 2018-11-13
Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
Hutchmed
Phase 1 Completed